论文部分内容阅读
中国科学院原子能研究所,于1970年底试制成功医用放射性同位素新品种鉬~(99-)鍀~(99m)、锡~(113)-銦~(113m)发生器(以下简称“发生器”)。1970年底到1971年4,5月间,北京药品生物制品检定所与原子能所、中国医学科学院及北京市有关医院协作,将“发生器”试用于甲状腺、脑、肝、肾等器官的扫描,并对共理化、生物学性质进行了检定。1971年6月在中国科学院、卫生部和北京市卫生局领导下,成立了北京“发生器”临床协作组。1971年10月又在上海进行推广。1972年5月由卫生部委托北京市卫生局举办了全国性的“发生器”进修班,29个省、市、自治区(除台湾省外)都参加了学习,为我
At the end of 1970, the Institute of Atomic Energy, Chinese Academy of Sciences, successfully produced molybdenum 99-, 99-, 113-, and 113m generators for medical radioisotopes (hereinafter referred to as “generators”). Between the end of 1970 and April and May 1971, Beijing Pharmaceutical and Biological Products Testing Institute collaborated with the Atomic Energy Agency, the Chinese Academy of Medical Sciences and relevant hospitals in Beijing to test the “generator” in the thyroid, brain, liver and kidney organs, And physical and biological nature of the test. June 1971 In the Chinese Academy of Sciences, Ministry of Health and Beijing Municipal Health Bureau under the leadership of the Beijing “generator” clinical cooperation group. 1971 October again in Shanghai to promote. May 1972 By the Ministry of Health commissioned the Beijing Municipal Health Bureau to hold a national “generator” class, 29 provinces, municipalities and autonomous regions (except Taiwan Province) have participated in the study for me